{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:15:03Z","timestamp":1785798903542,"version":"3.56.0"},"reference-count":34,"publisher":"Informa UK Limited","issue":"2","funder":[{"DOI":"10.13039\/100005565","name":"Janssen Global Services, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.2217\/imt-2020-0266","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T08:10:20Z","timestamp":1606205420000},"page":"143-154","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Front-Line Daratumumab-VTd Versus Standard-of-Care in ASCT-Eligible Multiple Myeloma: Matching-Adjusted Indirect Comparison"],"prefix":"10.1080","volume":"13","author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[{"name":"Service d\u2019H\u00e9matologie Clinique, University Hospital H\u00f4tel-Dieu, Nantes44000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hebraud","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer-Oncopole & Centre de Recherches en Cancerologie de Toulouse, Toulouse31100, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"University of Lille, CHU Lille, Service des Maladies du Sang, Lille59000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"CHU Poitiers \u2013 H\u00f4pital la Mil\u00e9trie, Poitiers86021, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Haut Leveque, University Hospital Bordeaux, Bordeaux33600, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hashim","sequence":"additional","affiliation":[{"name":"Ingress Health, Rotterdam, 3012 NJ, The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Hu","sequence":"additional","affiliation":[{"name":"Ingress Health, Rotterdam, 3012 NJ, The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[{"name":"H\u00f4pital Du Bocage, Centre Hospitalier Universitaire Dijon, Dijon21000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lofti","family":"Benboubker","sequence":"additional","affiliation":[{"name":"H\u00f4pital de Bretonneau, Centre Hospitalier R\u00e9gional Universitaire de Tours, Tours37000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam1182 DB, The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[{"name":"University Hospital Heidelberg, Internal Medicine V & National Center for Tumor Diseases (NCT), Heidelberg69120, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"University Medical Center of Hamburg-Eppendorf, Hamburg20251, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Salwender","sequence":"additional","affiliation":[{"name":"Asklepios Tumorzentrum Hamburg, AK Altona & AK St. Georg, Hamburg20099, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias K","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg69120, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"University Hospital Heidelberg, Internal Medicine V & National Center for Tumor Diseases (NCT), Heidelberg69120, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[{"name":"University Hospital Heidelberg, Internal Medicine V & National Center for Tumor Diseases (NCT), Heidelberg69120, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vanquickelberghe","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Beerse2340, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kampfenkel","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Leiden2333, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla de","family":"Boer","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Leiden2333, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanimira","family":"Krotneva","sequence":"additional","affiliation":[{"name":"Evidera PPD, Montreal, QuebecB0E 2K0, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Proskorovsky","sequence":"additional","affiliation":[{"name":"Evidera PPD, Montreal, QuebecB0E 2K0, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-3713","authenticated-orcid":false,"given":"Jianming","family":"He","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Lee","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cote","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center Cancer Institute, Rotterdam 3015 GD, The\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0049"},{"key":"e_1_3_5_6_1","unstructured":"DARZALEX \u00ae [Prescribing Information]\n. Janssen Biotech Inc PA USA (2020)."},{"key":"e_1_3_5_7_1","unstructured":"DARZALEX 20 mg\/mL concentrate for solution for infusion [Summary of Product Characteristics]\n. Janssen-Cilag International NV Beerse Belgium (2020)."},{"key":"e_1_3_5_8_1","unstructured":"DALINVI \u00ae (daratumumabe) solu\u00e7\u00e3o para dilui\u00e7\u00e3o injet\u00e1vel [Prescribing Information]. Janssen-Cilag Farmaceutica S\u00e3o Paulo Brazil (2018)."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355081"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-693580"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0271-1"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.80"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0724-1"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_3_5_21_1","unstructured":"Bristol Research University of Bristol\n. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. https:\/\/research-information.bris.ac.uk\/files\/94868463\/Population_adjustment_TSD_FINAL.pdf"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_5_23_1","volume-title":"International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting.","author":"Hashim M","year":"2018","unstructured":"Hashim M , HeJ , HuPet al. Is there a consensus regarding clinically relevant non-inferiority margins used for key oncology endpoints in non-inferiority oncology trials? PRM112. Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting.MD, USA (May 19\u201323, 2018)."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000241"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.274"},{"key":"e_1_3_5_28_1","volume-title":"European Hematology Association Annual Meeting.","author":"Rosi\u00f1ol L","year":"2019","unstructured":"Rosi\u00f1ol L , HebraudB , OriolAet al. Bortezomib-lenalidomide-dexamethasone vs bortezomib-thalidomide-dexamethasone induction: integrated analysis of randomized controlled trials in transplant-eligible newly diagnosed multiple myeloma. PF594. Presented at: European Hematology Association Annual Meeting.Amsterdam, The Netherlands (June 13\u201316, 2019)."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1459609"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.02.018"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1682571"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2020-0266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:23:22Z","timestamp":1715991802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2020-0266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.2217\/imt-2020-0266"],"URL":"https:\/\/doi.org\/10.2217\/imt-2020-0266","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}